Cerecor Inc (NASDAQ:CERC) saw a large decrease in short interest during the month of November. As of November 29th, there was short interest totalling 674,300 shares, a decrease of 18.3% from the November 14th total of 825,600 shares. Currently, 2.0% of the company’s shares are short sold. Based on an average daily volume of 58,500 shares, the days-to-cover ratio is currently 11.5 days.

Shares of Cerecor stock traded up $0.01 on Friday, hitting $4.41. 130,819 shares of the company’s stock traded hands, compared to its average volume of 76,433. The company has a fifty day moving average of $3.48 and a two-hundred day moving average of $3.91. Cerecor has a one year low of $2.71 and a one year high of $7.65. The company has a quick ratio of 0.71, a current ratio of 0.73 and a debt-to-equity ratio of 0.78.

Cerecor (NASDAQ:CERC) last issued its earnings results on Thursday, November 14th. The company reported ($0.07) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.06. Cerecor had a negative return on equity of 121.32% and a negative net margin of 113.66%. The business had revenue of $5.61 million during the quarter, compared to the consensus estimate of $5.15 million. Equities research analysts anticipate that Cerecor will post -0.4 EPS for the current year.

Several hedge funds have recently made changes to their positions in CERC. Wells Fargo & Company MN bought a new stake in shares of Cerecor in the 2nd quarter valued at $853,000. JPMorgan Chase & Co. lifted its position in shares of Cerecor by 612.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 72,670 shares of the company’s stock valued at $355,000 after acquiring an additional 62,473 shares during the period. Charles Schwab Investment Management Inc. bought a new position in Cerecor during the second quarter worth $288,000. Bank of New York Mellon Corp boosted its stake in Cerecor by 294.9% during the second quarter. Bank of New York Mellon Corp now owns 57,428 shares of the company’s stock worth $312,000 after acquiring an additional 42,885 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in Cerecor by 47.4% in the second quarter. Northern Trust Corp now owns 55,971 shares of the company’s stock worth $304,000 after purchasing an additional 17,999 shares during the period. 60.84% of the stock is owned by institutional investors.

A number of equities research analysts have recently commented on CERC shares. LADENBURG THALM/SH SH reiterated a “buy” rating and set a $10.00 price objective on shares of Cerecor in a research report on Friday, December 6th. ValuEngine downgraded shares of Cerecor from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Maxim Group restated a “buy” rating and issued a $10.00 target price on shares of Cerecor in a report on Friday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target (up previously from $11.00) on shares of Cerecor in a research report on Monday, December 2nd. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $10.67.

Cerecor Company Profile

Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device.

See Also: Strike Price

Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.